Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Eun Jeong Ban 1 Article
Clinical Study
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinol Metab. 2021;36(1):96-105.   Published online February 24, 2021
  • 5,712 View
  • 185 Download
  • 14 Web of Science
  • 12 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Several cancers show increased levels of lactate dehydrogenase A (LDHA), which are associated with cancer progression. However, it remains unclear whether LDHA levels are associated with papillary thyroid cancer (PTC) aggressiveness or with the presence of the PTC prognostic marker, the BRAFV600E mutation. This study aimed to evaluate the potential of LDHA as a PTC prognostic marker.
LDHA expression was examined in 83 PTC tissue specimens by immunohistochemistry. Human thyroid cell lines were genetically manipulated to overexpress BRAFV600E or were treated with a BRAF-specific short hairpin RNA (shBRAF), whose effects on LDHA expression were evaluated by Western blotting. Data from 465 PTC patients were obtained from The Cancer Genome Atlas (TCGA) database and analyzed to validate the in vitro results.
LDHA was aberrantly overexpressed in PTC. Intense immunostaining for LDHA was observed in PTC specimens carrying mutated BRAF, whereas the intensity was less in wild-type BRAF samples. Overexpression of BRAFV600E resulted in LDHA upregulation, whereas treatment with shBRAF downregulated LDHA in human thyroid cell lines. Furthermore, LDHA mRNA expression was significantly elevated and associated with BRAFV600E expression in thyroid cancer tissues from TCGA database. Additionally, LDHA overexpression was found to be correlated with aggressive clinical features of PTC, such as lymph node metastases and advanced tumor stages.
LDHA overexpression is associated with the BRAFV600E mutation and an aggressive PTC behavior. Therefore, LDHA may serve as a biomarker and therapeutic target in PTC.


Citations to this article as recorded by  
  • Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
    Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J. Houlton, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Neal Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato G. Martins, Jonathan R. Fromm, Cristina P. Rodriguez
    Cancer Medicine.2023; 12(8): 9384.     CrossRef
  • LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer
    Liang Shi, Rui Duan, Zhenhua Sun, Qiong Jia, Wenyu Wu, Feng Wang, Jianjun Liu, Hao Zhang, Xue Xue
    Cell Death & Differentiation.2023; 30(6): 1517.     CrossRef
  • Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
    Guochao Ye, Xiaomei Zhang, Mansheng Li, Zixiang Lin, Yongcan Xu, Haoru Dong, Jie Zhou, Jiaqi Zhang, Sheng Wang, Yunping Zhu, Xiaobo Yu, Xu Qian
    BMC Cancer.2023;[Epub]     CrossRef
  • Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
    Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa
    British Journal of Cancer.2023; 129(2): 249.     CrossRef
  • circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
    Hongguo Xie, Xiaopeng Lu
    Open Medicine.2023;[Epub]     CrossRef
  • The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
    Sai-li Duan, Min Wu, Zhe-Jia Zhang, Shi Chang
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma
    Hui-feng Wu, Hao Liu, Zhe-wei Zhang, Ji-min Chen
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease
    Jaime Eduardo Pachón Suárez, Marcela C. Salazar, Victor Z. Rizo
    Plastic and Reconstructive Surgery - Global Open.2022; 10(2): e4137.     CrossRef
  • Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
    Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
    Endocrinology and Metabolism.2022; 37(1): 53.     CrossRef
  • Drug delivery for metabolism targeted cancer immunotherapy
    Taravat Khodaei, Sahil Inamdar, Abhirami P. Suresh, Abhinav P. Acharya
    Advanced Drug Delivery Reviews.2022; 184: 114242.     CrossRef
  • Sulfur quantum dot based fluorescence assay for lactate dehydrogenase activity detection
    Shengnan Fan, Xiaoqing Li, Fanghui Ma, Minghui Yang, Juan Su, Xiang Chen
    Journal of Photochemistry and Photobiology A: Chemistry.2022; 430: 113989.     CrossRef
  • STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
    Nan Huo, Rui Cong, Zhi-jia Sun, Wen-chao Li, Xiang Zhu, Chun-yuan Xue, Zhao Chen, Lu-yuan Ma, Zhong Chu, Yu-chen Han, Xiao-feng Kang, Song-hao Jia, Nan Du, Lei Kang, Xiao-jie Xu
    Cell Death & Disease.2021;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism